SecBot SecBot
8-K ·Filed Jul 15, 2026

JNJ

JOHNSON & JOHNSON
BULLISH
Impact 6/10
Horizonweeks Processed4mo ago SEC0000200406-26-000146
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The raised guidance and strong operational momentum across both segments support a positive outlook. Monitor STELARA erosion trajectory and the new supply chain restructuring costs. The stock may see modest upside as the beat was small but guidance raise confirms underlying strength.

DirectionBullish
Confidencehigh
Horizonweeks

Drugs in focus

JNJ drug pipeline →

DARZALEX

▲ Bullish Named in this 8-K
Impact
Phase
Approved (multiple FDA-approved multiple-myeloma indications); additional label-expansion Phase 3 studies completed.
Time to market
Already approved and on the market — DARZALEX (IV) since Nov 2015 and DARZALEX FASPRO (subcutaneous) since May 2020; label expansion for newly diagnosed multiple myeloma added ~Jan 2026.
Next catalyst
None dated

What to watchFor JNJ shareholders, DARZALEX is a cash-cow growth driver, not a binary, treat it as part of the Innovative Medicine growth story (with CARVYKTI, TREMFYA, SPRAVATO) that supported the FY2026 guidance raise, and watch each Genmab 6-K for quarterly DARZALEX net sales as the cleanest read on the franchise. The bigger near-term event to track is competitive: Bristol Myers' iberdomide + daratumumab + dexamethasone PDUFA landed Aug 17, 2026, and BMY's bb2121 CAR-T Phase 3 readout is pending.

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$247.02
T+0 close · Jul 15, 2026 · via day close
Latest settled
+3.83%
T+60 · $256.48
Vs SPY
+1.30%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 15 $247.02entry
  2. T+1 · 4mo ago +1.19%α +1.74% · $249.97
  3. T+5 · 4mo ago +3.49%α +4.47% · $255.63
  4. T+20 · 3mo ago +5.59%α +3.25% · $260.84
  5. T+60 · 6w ago +3.83%α +1.30% · $256.48
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

JNJ reported Q2 2026 adjusted EPS of $2.90, a 1.6% beat vs. consensus of $2.85, on revenue of $25.31B (6.6% YoY growth, slightly above $25.06B consensus). The company raised its full-year 2026 adjusted EPS guidance by $0.13 to $11.68 at the midpoint (8.2% YoY growth) and raised its reported sales guidance to $101.1B at the midpoint (7.3% YoY growth). Strong performance was driven by Innovative Medicine (DARZALEX, CARVYKTI, TREMFYA, SPRAVATO) and MedTech (Cardiovascular, Surgery), partially offset by STELARA erosion from biosimilar competition.

Key Financial Metrics

EPS
$2.90
est $2.85 · +1.8%
Revenue
$25.3B
est $25.1B · +1.0% · +6.6% YoY
Rating
beat
Guidance
$100.8B-$101.4B
raised
Free Cash Flow
$8.7B
Gross Margin
68.2%

Key Facts

  • Q2 2026 reported sales of $25.31B, up 6.6% YoY, with operational growth of 5.6% and adjusted operational growth of 5.7%
  • Adjusted EPS of $2.90 beat consensus of $2.85 by 1.6%
  • Full-year 2026 adjusted EPS guidance raised by $0.13 to $11.68 midpoint (8.2% YoY growth)
  • Full-year 2026 reported sales guidance raised to $101.1B midpoint (7.3% YoY growth)
  • Innovative Medicine sales grew 7.8% reported (6.8% operational), driven by DARZALEX (+18.9%), CARVYKTI (+49.4%), TREMFYA (+72.5%), SPRAVATO (+40.8%), and CAPLYTA (+70.9%)
  • MedTech sales grew 4.5% reported (3.6% operational), led by Cardiovascular (+4.0%) and Surgery (+3.9%)
  • STELARA declined 55.2% YoY due to biosimilar competition, an approximate 760 bps drag on Innovative Medicine growth
  • Free cash flow (YTD) estimated at $8.7B vs $6.2B in prior year period
  • New supply chain restructuring program initiated in Innovative Medicine with estimated costs of $650-$750M through FY2029

Financial Impact

Q2 revenue $25.31B (+6.6% YoY), adjusted EPS $2.90 (+4.7% YoY); FY2026 guidance raised to $101.1B sales and $11.68 adjusted EPS at midpoints

revenueepsguidancefree cash flow

Risk Factors

  • STELARA biosimilar erosion continues to pressure Immunology segment (55.2% decline in Q2)
  • New supply chain restructuring program adds $650-$750M in costs through FY2029
  • Litigation-related adjustments of $267M in Q2 remain a recurring headwind
  • MedTech growth of 3.6% operational is below the overall company rate

Market Snapshot

Price
$250.00
Volume
100
Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
68% bullish (31 analysts)

Investment Themes

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0000200406-26-000146
Document: a2026q2exhibit991.htm0000200406-26-000146
Document: jnj-20260715.htm0000200406-26-000146
Document: 0000200406-26-000146-index-headers.html0000200406-26-000146
Document: 0000200406-26-000146-index.html0000200406-26-000146
Document: 0000200406-26-000146.txt0000200406-26-000146
8-K Data (Synthetic)0000200406-26-000146

Track record

21 reports on JNJ

Performance horizon

3 of 4 bullish or bearish reports moved the stock their way by T+60. Best: +13.24% at T+60 after the May 13, 2026 report. 5 of 5 went positive at some point.

Filters
  1. Nov 16, 2026today Institutional Cluster Mixed 3/10 Entry $289.75 Now $282.55 −2.48% settles Feb 12
  2. Nov 12, 20264d ago 144 Neutral 2/10 Entry $283.52 Now $282.55 −0.34% settles Feb 10
  3. Oct 13, 20264w ago 8-K Mixed 6/10 Entry $248.61 Now $282.55 +13.65% settles Jan 8
  4. Sep 30, 20266w ago Court Ruling Bullish 6/10 Entry $258.66 Now $282.55 +9.24% settles Dec 28
  5. Sep 24, 20267w ago Court Ruling Neutral 3/10 Entry $271.22 Now $282.55 +4.18% settles Dec 21
  6. Sep 9, 20269w ago Court Ruling Neutral 1/10 Entry $266.35 Now $282.55 +6.08% settles Dec 4
  7. Aug 18, 202612w ago Insider Cluster Neutral 2/10 Entry $273.41 to $283.52 Now $282.55 +3.34% ▲ +3.70% +5.25% vs SPY
  8. Aug 14, 202613w ago Insider Cluster Neutral 2/10 Entry $262.37 to $280.78 Now $282.55 +7.69% ▲ +7.02% +9.96% vs SPY
  9. Aug 7, 202614w ago Insider Cluster Neutral 3/10 Entry $261.81 to $266.17 Now $282.55 +7.92% ▲ +1.67% +4.08% vs SPY
  10. Aug 7, 202614w ago Court Ruling Bearish 4/10 Entry $261.81 to $266.17 Now $282.55 −7.92% ▼ −1.67% −4.08% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens in 5h 21m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 15, 2026